Sort   by:  
 Page size 
UnknownT<sub>SCM</sub>-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial.
Not available
S-EPMC12644732 | biostudies-literature
UnknownFirst-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Not available
S-EPMC9433959 | biostudies-literature
UnknownctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.
Not available
S-EPMC7618057 | biostudies-literature
UnknownTherapeutic misunderstandings in modern research.
Not available
S-EPMC10952669 | biostudies-literature
UnknownCAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.
Not available
S-EPMC12848364 | biostudies-literature
UnknownAfrican Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Not available
S-EPMC7736245 | biostudies-literature
UnknownBeta adrenergic blockade reduces utilitarian judgement.
Not available
S-EPMC3573226 | biostudies-literature
UnknownDurvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Not available
S-EPMC9937097 | biostudies-literature
UnknownMyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors.
Not available
S-EPMC10824375 | biostudies-literature
UnknownXaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Not available
S-EPMC10784743 | biostudies-literature
Sort   by:  
 Page size